Navrogen Awarded National Cancer Institute Grant to Develop Next-Generation Rituximab With Enhanced Therapeutic Effects

Cheyney, PA, September 14, 2020 -- Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announced today that it has been awarded a National Cancer Institute (NCI) R03 Grant to support its NAV-006 program involving the development of a next-generation rituximab that is refractory to the immuno-suppressive effects of the tumor microenvironment.

read more

NAVROGEN AND LEVENA ANNOUNCE COLLABORATION TO DEVELOP ANTIBODY DRUG CONJUGATES TO TREAT HUMORAL IMMUNO-SUPPRESSED CANCERS

Cheyney, PA, and San Diego, CA, February 4, 2020 -- Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, and Levena Biopharma, a company specialized in developing antibody drug conjugates (ADCs), announced today the expanded collaboration to develop ADCs targeting humoral immuno-suppressed cancers. ADCs developed under this collaboration combine Levena’s linker and cytotoxic payload chemistry expertise along with Navrogen’s cancer-targeting antibodies discovered using its proprietary Humoral Immuno Oncology (HIO) platform technologies.

read more

NAVROGEN OPENS R&D OPERATIONS AT CHEYNEY UNIVERSITY

Cheyney, PA, January 31, 2020 -- Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announced the opening of its R&D operations at the Cheyney University science center located in Chester County, PA. The move enables the company to expand its proprietary Humoral Immuno Oncology (HIO) technology discovery efforts to identify HIO-suppressed cancer types and development of therapeutic agents that can unlock a patient’s immune system to combat their cancer.

read more

NAVROGEN ANNOUNCES THE CLOSING OF $3.2M FUNDING TO SUPPORT ITS HUMORAL IMMUNO-ONCOLOGY PLATFORM DISCOVERY TECHNOLOGIES AND PRECLINICAL PIPELINE

Philadelphia, PA, September 17, 2019 -- Navrogen, Inc. announced today that it has raised $3.2M in convertible note financing to support its operations, Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities. The financing was led by Ben Franklin Technology Partners of South Eastern Pennsylvania and a number of private investors. 

read more